Renaissance Technologies’s Edesa Biotech EDSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-25,000
Closed -$61.8K 3367
2025
Q3
$61.8K Buy
+25,000
New +$57.8K ﹤0.01% 3316
2023
Q2
Sell
-2,500
Closed -$16K 4007
2023
Q1
$16K Buy
+2,500
New +$26.1K ﹤0.01% 3848
2022
Q3
Sell
-6,607
Closed -$74K 4094
2022
Q2
$74K Sell
6,607
-5,222
-44% -$77K ﹤0.01% 3914
2022
Q1
$246K Buy
11,829
+7,100
+150% +$197K ﹤0.01% 3557
2021
Q4
$186K Buy
+4,729
New +$226K ﹤0.01% 3534
2021
Q1
Sell
-10,586
Closed -$315K 3407
2020
Q4
$315K Buy
+10,586
New +$433K ﹤0.01% 3016
2020
Q1
Sell
-3,582
Closed -$103K 3516
2019
Q4
$103K Buy
3,582
+1,332
+59% +$47.1K ﹤0.01% 3318
2019
Q3
$98K Sell
2,250
-812
-27% -$29.5K ﹤0.01% 3263
2019
Q2
$151K Buy
3,062
+1,659
+118% +$73K ﹤0.01% 3342
2019
Q1
$64K Buy
1,403
+226
+19% +$11.1K ﹤0.01% 3347
2018
Q4
$45K Buy
1,177
+708
+151% +$33.1K ﹤0.01% 3293
2018
Q3
$27K Buy
+469
New +$29.9K ﹤0.01% 3313
2018
Q1
Sell
-169
Closed -$40K 3407
2017
Q4
$40K Buy
+169
New +$53.8K ﹤0.01% 3273

Other funds holding EDSA

Renaissance Technologies's EDSA Position: Q4 2025 in Review

Renaissance Technologies sold out of Edesa Biotech (EDSA) in Q4 2025, closing a stake of 25,000 shares — an estimated $61.8K sold.

Renaissance Technologies first reported a position in EDSA in Q4 2017 and held it in 13 quarters. The position peaked at $315K in Q4 2020. 22 funds tracked by Wall St. Rank hold EDSA as of Q4 2025.

  • Renaissance Technologies reported no remaining Edesa Biotech position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 25,000 Edesa Biotech shares in Q4 2025, an estimated $61.8K.
  • Renaissance Technologies first reported a position in Edesa Biotech in Q4 2017 and held it in 13 quarters.
  • Renaissance Technologies's Edesa Biotech position peaked at $315K in Q4 2020.
  • 22 funds tracked by Wall St. Rank held Edesa Biotech as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.